Stockscreener 앱 받기
41.03
1.61%
0.65
시간 외 거래:
41.03
전일 마감가:
$40.38
열려 있는:
$39.91
하루 거래량:
1.28M
Relative Volume:
0.54
시가총액:
$8.46B
수익:
$2.09B
순이익/손실:
$424.88M
주가수익비율:
20.07
EPS:
2.0439
순현금흐름:
$447.20M
1주 성능:
+3.32%
1개월 성능:
-15.97%
6개월 성능:
-11.27%
1년 성능:
+2.52%
1일 변동 폭
$39.75
$41.10
1주일 범위
$38.80
$41.10
52주 변동 폭
$38.13
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
41.03 | 8.46B | 2.09B | 424.88M | 447.20M | 2.0439 |
TMO
Thermo Fisher Scientific Inc
|
491.46 | 182.57B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
191.12 | 135.26B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
569.55 | 45.24B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
115.48 | 32.63B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
304.24 | 29.85B | 3.17B | 642.63M | 516.49M | 10.77 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-13 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2026-01-22 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-06-24 | 개시 | Barclays | Overweight |
| 2025-04-04 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-10-17 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2024-06-27 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-07 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-09-12 | 개시 | Robert W. Baird | Outperform |
| 2023-05-23 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-01-18 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-10-14 | 개시 | Redburn | Buy |
| 2021-07-14 | 다운그레이드 | Kepler | Buy → Hold |
| 2021-06-03 | 개시 | Goldman | Neutral |
| 2020-10-06 | 재개 | BofA Securities | Buy |
| 2020-09-28 | 업그레이드 | Kepler | Hold → Buy |
| 2020-08-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-20 | 재개 | JP Morgan | Overweight |
| 2020-08-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2020-08-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2020-08-14 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | 다운그레이드 | Berenberg | Buy → Hold |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-12-26 | 재개 | BofA/Merrill | Underperform |
| 2019-11-15 | 개시 | Stifel | Hold |
| 2019-11-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-11-14 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2019-11-14 | 업그레이드 | Kepler | Reduce → Hold |
| 2019-10-17 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | 다운그레이드 | Kepler | Hold → Reduce |
| 2019-10-08 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-10-08 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
Qiagen Nv 주식(QGEN)의 최신 뉴스
Momentum Shift: Why is Qiagen NV stock going up2026 Pullback Review & Community Trade Idea Sharing Platform - baoquankhu1.vn
Qiagen (QGEN) upgraded to buy by Deutsche Bank after 30% decline - MSN
Qiagen N.V. (NYSE:QGEN) Given Average Rating of "Hold" by Brokerages - MarketBeat
Qiagen N.V. (QGEN) Rolls Out QIAstat-Dx Rise, Expands U.S. Testing Access - MSN
Qiagen N.V. (QIA.DE) stock price, news, quote and history - Yahoo Finance UK
Molecular Diagnostics Market Size is Expected to Reach USD 43.50 Billion by 2035 Owing to the Surging Demand for Accurate and Early Disease Detection Globally | SNS Insider - GlobeNewswire Inc.
Bank of America Discloses 3.01% Voting Stake in Qiagen - TipRanks
Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen (QGEN) Upgraded to Buy by Deutsche Bank After 30% Decline - Insider Monkey
QGEN Technical Analysis & Stock Price Forecast - intellectia.ai
Bruker appoints QIAGEN CEO Thierry Bernard to board of directors By Investing.com - Investing.com Australia
Qiagen N.V. Stock: Leader in Molecular Diagnostics Faces CEO Transition Amid Steady Growth Outlook - ad-hoc-news.de
Bruker appoints QIAGEN CEO Thierry Bernard to board of directors - Investing.com
List of 26 Acquisitions by Qiagen (Apr 2026) - Tracxn
Bear Alert: Whats next for Qiagen NV stock2026 Weekly Recap & Risk Managed Investment Strategies - baoquankhu1.vn
Qiagen N.V. Stock: Oversold Opportunity in Sample-to-Insight Leader Amid Biotech Sector Shifts - ad-hoc-news.de
Allspring Global Investments Holdings LLC Boosts Position in Qiagen N.V. $QGEN - MarketBeat
QGEN Stock Price, Quote & Chart | QIAGEN N.V. (NYSE:QGEN) - ChartMill
QIAGEN NV Hits New 52-Week Low at USD 38.80 Amid Declining Performance - Markets Mojo
AlphaValue/Baader Europe Upgrades Qiagen to Buy - marketscreener.com
The Bull Case For Qiagen (QGEN) Could Change Following New QuantiFERON-TB Gold Plus EvidenceLearn Why - simplywall.st
Qiagen (QGEN) Valuation Check As New QuantiFERON TB Data Reinforces Leadership In Tuberculosis Detection - Sahm
Qiagen NV at Leerink Global Healthcare Conference Transcript - GuruFocus
Qiagen (NYSE:QGEN) Cut to "Hold" at Wall Street Zen - MarketBeat
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen N.V. Stock: Steady Position in Molecular Diagnostics Amid Sector Growth Opportunities - AD HOC NEWS
Qiagen (NYSE:QGEN) Sets New 52-Week LowTime to Sell? - MarketBeat
Aug Highlights: Should I set a stop loss on Qiagen NVProfit Target & High Conviction Investment Ideas - baoquankhu1.vn
Qiagen N.V. Stock: A Core Player in Molecular Diagnostics for Long-Term Investor Focus - AD HOC NEWS
QIAGEN NV Hits New 52-Week Low at USD 39.26 Amid Ongoing Decline - Markets Mojo
Qiagen N.V. stock faces pressure amid biotech sector volatility and recent market caution - AD HOC NEWS
Qiagen N.V. stock faces pressure amid biotech sector volatility and recent price dip on Frankfurt ex - AD HOC NEWS
Portfolio Update: How does Qiagen NV score in quality rankings2026 Geopolitical Influence & Verified Short-Term Plans - baoquankhu1.vn
Aug Gainers: Can Qiagen NV ride the EV waveTrade Volume Report & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Should You Add QIAGEN Stock to Your Portfolio for Now? - MSN
Why is Qiagen (QGEN) down 9.4% since last earnings report? - MSN
AI in Omics Studies Market is Going to Boom | Major Giants QIAGEN, Microsoft, NVIDIA - openPR.com
JPMorgan Chase & Co. Has $33.09 Million Stake in Qiagen N.V. $QGEN - MarketBeat
Qiagen N.V. stock faces pressure amid genomics slowdown as DACH investors eye biotech resilience - AD HOC NEWS
Breakout Zone: Is Qiagen NV part of any major index2026 Volume & Daily Growth Stock Investment Tips - baoquankhu1.vn
Tracer Biotechnologies and QIAGEN to advance blood-based MRD testing for solid tumors - MSN
Institution Moves: Is Qiagen NV stock a smart retirement pick2026 Investor Takeaways & Growth Focused Entry Point Reports - baoquankhu1.vn
QIAGEN reports supervisory board member’s restricted stock unit vesting and share settlement - TipRanks
Agilent, Danaher could be potential buyers of Qiagenanalyst - MSN
Fundamentals Check: Does Qiagen NV align with a passive investing strategy2026 Sector Moves & Weekly Chart Analysis and Guides - baoquankhu1.vn
Qiagen N.V. stock rises on strong Q4 earnings and genomics demand surge amid AI biotech push - AD HOC NEWS
Qiagen Announces Form 20-F Annual Report Filing for 2025 Results - pharmiweb.com
Qiagen (NYSE:QGEN) Hits New 12-Month LowShould You Sell? - MarketBeat
PTA-CMS: QIAGEN N.V.: Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act] - TradingView
Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act] - TradingView
Qiagen N : Annual Report for Fiscal Year Ending December 31, 2025 (Form 20-F) - MarketScreener
Qiagen Nv (QGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.17%
1.11%
자본화:
|
볼륨(24시간):